93. 原発性胆汁性胆管炎 Disease details / Clinical trials / Drug dev / DR info

1-20190
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria
11C-csar
   University of Aarhus
      2013   Phase 1   NCT01879735   Denmark
13-15MG/KG/D ursodeoxycholic
   West China Hospital
      2018   Phase 4   NCT03345589   China
18-22MG/KG/D ursodeoxycholic
   West China Hospital
      2018   Phase 4   NCT03345589   China
2MG CS0159
   Cascade Pharmaceuticals, Inc
      2023   Phase 2   NCT05896124   China
3 MG [14C]-A4250 capsule
   Albireo
      2017   Phase 1   NCT03082937   United Kingdom
3-({[(3R,5R)-3-butyl-3-ethyl-7-(methyloxy)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,4-benzothiazepin-8-YL]methyl}amino)pentanedioic acid
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-000007-21-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000007-21-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000007-21-CZ   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000007-21-FR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000007-21-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
3A,7A-dihydroxy-6A-ethyl-5ßcholan-24-OIC acid
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom
6 alpha-ethylchenodeoxycholic acid (6-edca), OCA, INT-747
   INTERCEPT PHARMACEUTICALS INC.
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
6-ecdca
   INTERCEPT PHARMACEUTICALS INC.
      2022   Phase 2   EUCTR2022-001241-20-IT   Argentina;Canada;Italy;Turkey;United States
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-NL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
6?-ethylchenodeoxycholic acid (6-ecdca), OCA, INT-747
   Intercept Pharmaceuticals Inc.
      2015   Phase 3   EUCTR2014-005012-42-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
6A-ethylchenodeoxycholic acid (6-ecdca), OCA, INT-747
   Intercept Pharmaceuticals Inc.
      2018   Phase 4   EUCTR2014-005012-42-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 4   EUCTR2014-005012-42-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005012-42-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
6A-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom
6A-ethylchenodeoxycholic acid , 6-ethylchenodeoxycholic acid, 3A,7A-dihydroxy-6A-ethyl-5ßcholan-24-O
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom
6A-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom
6A-ethylchenodeoxycholic acid, 6-ethylchenodeoxycholic acid, 3A,7A-dihydroxy-6A-ethyl-5ßcholan-24-O
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom
A11ha02
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom
A4250
   Albireo
      2013   Phase 1   NCT02963077   -
   Sahlgrenska Academy
      2014   Phase 2   EUCTR2014-004070-42-SE   Sweden
   Sahlgrenska University Hospital, Sweden
      2015   Phase 2   NCT02360852   Sweden
Abatacept
   Christopher Bowlus, MD
      2014   Phase 4   NCT02078882   United States
Acido obeticolico
   INTERCEPT PHARMACEUTICALS INC.
      2022   Phase 2   EUCTR2022-001241-20-IT   Argentina;Canada;Italy;Turkey;United States
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
Acido ursodessicolico
   DR. FALK PHARMA GMBH
      2009   Phase 3   EUCTR2007-004040-70-IT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
Alkaline phosphatase
   You'an Hospital, Capital Medical University
      2020   -   ChiCTR2000032053   China
Alpha-ethylchenodeoxycholic acid (6-edca), OCA, INT-747
   INTERCEPT PHARMACEUTICALS INC.
      2022   Phase 2   EUCTR2022-001241-20-IT   Argentina;Canada;Italy;Turkey;United States
APD334
   Arena Pharmaceuticals
      2017   Phase 2   NCT03155932   Australia;New Zealand;United States
ASC42 10 MG
   Gannex Pharma Co., Ltd.
      2022   Phase 2   NCT05190523   China
ASC42 15 MG
   Gannex Pharma Co., Ltd.
      2022   Phase 2   NCT05190523   China
ASC42 5 MG
   Gannex Pharma Co., Ltd.
      2022   Phase 2   NCT05190523   China
Atorvastatin
   Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology
      2005   -   EUCTR2005-002160-28-AT   Austria
   Medical University of Graz
      2006   Phase 3   NCT00844402   Austria
Babaodan capsule
   Mei Han
      2024   Phase 4   NCT06371196   -
Baricitinib
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 2   EUCTR2018-003365-34-IT   Italy;United Kingdom;United States
   Eli Lilly and Company
      2019   Phase 2   NCT03742973   Italy;Puerto Rico;United Kingdom;United States
      2019   Phase 2   EUCTR2018-003365-34-GB   Italy;United Kingdom;United States
BCD-085
   Biocad
      2018   Phase 2   NCT03476993   Russian Federation
Bezafibrat genericon retard 400 MG
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria
Bezafibrate
   Academic Medical Center
      2017   Phase 2   EUCTR2014-001438-27-ES   Netherlands;Spain
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2016   Phase 3   NCT02701166   Netherlands;Spain
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 3   NCT01654731   France
   Gunma Liver Study Group
      2003   -   JPRN-C000000225   Japan
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2016   Phase 3   NCT02937012   Mexico
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria
   Shinshu University Faculty of Medicine, Department of Gastroenterology
      2020   -   JPRN-UMIN000039350   Japan
Bezafibrate 100 MG
   Intercept Pharmaceuticals
      2022   Phase 2   NCT05239468   United States
Bezafibrate 200 MG
   Intercept Pharmaceuticals
      2022   Phase 2   NCT05239468   United States
      2019   Phase 2   NCT04594694   Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
Bezafibrate 200 MG IN addition TO udca therapy
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 3   NCT06443606   France
Bezafibrate 200 MG oral tablet
   Instituto Mexicano del Seguro Social
      2020   Phase 3   NCT04751188   Mexico
Bezafibrate 400 MG
   Intercept Pharmaceuticals
      2019   Phase 2   NCT04594694   Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
Bezafibrate 400 MG IN addition TO udca therapy
   Assistance Publique - Hôpitaux de Paris
      2024   Phase 3   NCT06443606   France
Bezafibrate IR
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
Bezafibrate SR
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
Bezafibrate, beza, BZF, bezalip
   INTERCEPT PHARMACEUTICALS INC.
      2022   Phase 2   EUCTR2022-001241-20-IT   Argentina;Canada;Italy;Turkey;United States
Bezafibrate, beza, BZF, bezalip mono
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
Bezafilbrate IR
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
Bezalip
   Academic Medical Center
      2017   Phase 2   EUCTR2014-001438-27-ES   Netherlands;Spain
      2015   -   EUCTR2014-001438-27-NL   Netherlands
Biological: mesenchymal stem cell
   Robert Chunhua Zhao, MD, PhD
      2011   Phase 1   NCT01440309   China
Budesonide
   DR. FALK PHARMA GMBH
      2009   Phase 3   EUCTR2007-004040-70-IT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
   Dr. Falk Pharma GmbH
      2013   -   EUCTR2007-004040-70-PL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   Phase 3   NCT00746486   France;Germany
      2009   Phase 3   EUCTR2007-004040-70-GB   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004040-70-DK   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004040-70-AT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004040-70-SE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-NL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-LT   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-HU   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-FR   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-FI   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004040-70-ES   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-DE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
   Mayo Clinic
      2007   -   NCT00587119   United States
Calcium
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012489   Japan
      2013   -   JPRN-UMIN000012193   Japan
Cilofexor
   Gilead Sciences
      2016   Phase 2   NCT02943447   Austria;Canada;United Kingdom;United States
CNP-104
   COUR Pharmaceutical Development Company, Inc.
      2022   Phase 1/Phase 2   NCT05104853   United States
CNTO1275
   Janssen-Cilag International N.V.
      2011   -   EUCTR2011-000554-31-SE   Canada;France;Germany;Italy;Sweden;United Kingdom;United States
      2011   Phase 2   EUCTR2011-000554-31-GB   Canada;France;Germany;Italy;Sweden;United Kingdom;United States
Colchicine
   National Center for Research Resources (NCRR)
      1989   Phase 3   NCT00004748   -
Combination antiviral therapy
   University of Alberta
      2004   Phase 2/Phase 3   NCT00490620   Canada;United Kingdom;United States
CR845 1.0 MG
   Cara Therapeutics, Inc.
      2019   Phase 2   NCT03995212   United States
CS0159
   Cascade Pharmaceuticals, Inc
      2025   Phase 1   NCT06888115   China
      2023   Phase 1   NCT06098027   China
      2022   Phase 1   NCT05624294   China
Cyclophosphamide
   Traslational Research and Clinical Trial Center
      2012   Phase 1,2   JPRN-UMIN000015789   Japan
Cyclosporin A
   West China Hospital
      2021   Phase 4   NCT04376528   China
Denosumab
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012489   Japan
      2013   -   JPRN-UMIN000012193   Japan
   Tokai University School of Medicine
      2018   -   JPRN-UMIN000031384   Japan
E6011
   EA Pharma Co., Ltd.
      2017   Phase 2   NCT03092765   Japan
EDP-305
   Enanta Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2017-003528-62-BE   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003528-62-NL   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003528-62-GB   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003528-62-ES   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003528-62-DE   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
      2018   Phase 2   EUCTR2017-003528-62-AT   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
EDP-305 dose 1
   Enanta Pharmaceuticals
      2017   Phase 2   NCT03394924   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
EDP-305 dose 2
   Enanta Pharmaceuticals
      2017   Phase 2   NCT03394924   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
Elafibranor
   GENFIT
      2021   Phase 3   EUCTR2019-004941-34-IT   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004941-34-FR   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
   Genfit SA
      2018   Phase 2   EUCTR2016-003817-80-FR   France;Germany;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003817-80-GB   France;Germany;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003817-80-ES   France;Germany;Spain;United Kingdom;United States
   IPSEN Pharma SAS
      2021   Phase 3   EUCTR2019-004941-34-DE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004941-34-BE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Türkiye;United Kingdom;United States
   Ipsen
      2025   Phase 3   NCT06730061   Japan
      2024   Phase 3   NCT06383403   Czechia;France;Germany;Italy;Korea, Republic of;Poland;Romania;Spain;United Kingdom;United States
      2023   Phase 3   NCT06016842   Argentina;Australia;Belgium;Brazil;Canada;Chile;Czechia;Denmark;France;Italy;Korea, Republic of;Mexico;New Zealand;Poland;Romania;Spain;United States
   Ipsen Bioscience Inc
      2022   Phase 1   EUCTR2022-001883-91-FR   France
Elafibranor 120 MG
   Genfit
      2017   Phase 2   NCT03124108   France;Germany;Spain;United Kingdom;United States
Elafibranor 80 MG
   Genfit
      2017   Phase 2   NCT03124108   France;Germany;Spain;United Kingdom;United States
Elafibranor 80MG
   Ipsen
      2020   Phase 3   NCT04526665   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
Emtricitabine
   University of Alberta
      2021   Phase 2   NCT03954327   Canada
EP547
   Escient Pharmaceuticals, Inc
      2022   Phase 2   NCT05525520   Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
EP547 tablet 25MG
   Escient Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-002526-25-FR   Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
EP547 tablet 75MG
   Escient Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-002526-25-FR   Belgium;Canada;France;Israel;Netherlands;Spain;United Kingdom;United States
Ezetimibe
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom
Ezetrol
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom
EZT
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom
Fecal microbiota
   Peking Union Medical College Hospital
      2024   Phase 0   ChiCTR2400081306   China
Fenofibrate
   Beijing 302 Hospital
      2016   Phase 1/Phase 2   NCT02965911   China
   Han Ying
      2024   Early Phase 1   NCT06591455   China
      2023   Phase 2/Phase 3   NCT06174402   China
   Peking Union Medical College Hosipital
      2018   -   ChiCTR1800020160   China
   University of Florida
      2007   Phase 2   NCT00575042   United States
   University of Miami
      2011   Phase 2   NCT01141296   United States
   Xijing Hospital of Digestive Diseases
      2024   Phase 3   NCT06755151   China
      2017   Phase 2/Phase 3   NCT06365424   China
      2016   Phase 3   NCT02823366   China
      2016   Phase 3   NCT02823353   China
Fenofibrate 200MG
   Xijing Hospital of Digestive Diseases
      2023   Phase 2/Phase 3   NCT05749822   China
Fenofibrate combined with ursodeoxycholic acid
   Xijing Hospital of Digestive Diseases
      2023   Phase 3   NCT05751967   China
Fenofibrate IN combination with ursodeoxycholic acid
   Xijing Hospital of Digestive Diseases
      2024   Phase 3   NCT06755541   China
FFP104
   Fast Forward Pharmaceuticals
      2015   Phase 1/Phase 2   NCT02193360   Netherlands;United Kingdom
   Fast Forward Pharmaceuticals, B.V.
      2015   Phase 2   EUCTR2014-001638-27-GB   Netherlands;United Kingdom
      2014   Phase 2   EUCTR2014-001638-27-NL   Netherlands;United Kingdom
Fully human monoclonal antibody directed against CXCL10
   NovImmune S.A.
      2011   -   EUCTR2011-001326-26-GB   Italy;United Kingdom
Fuzhenghuayu
   Xijing Hospital of Digestive Diseases
      2016   Phase 3   NCT02916641   China
      2016   Phase 3   NCT02916290   China
Genetic analysis
   Mayo Clinic
      2002   -   NCT01161953   United States
GFT505
   GENFIT
      2021   Phase 3   EUCTR2019-004941-34-IT   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
      2021   Phase 3   EUCTR2019-004941-34-FR   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;Mexico;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States
   Genfit SA
      2018   Phase 2   EUCTR2016-003817-80-FR   France;Germany;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003817-80-GB   France;Germany;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-003817-80-ES   France;Germany;Spain;United Kingdom;United States
   IPSEN Pharma SAS
      2021   Phase 3   EUCTR2019-004941-34-DE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004941-34-BE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Türkiye;United Kingdom;United States
GKT137831
   GENKYOTEX SA
      2018   Phase 2   EUCTR2016-004599-23-IT   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
   Genkyotex SA
      2017   Phase 2   EUCTR2016-004599-23-GR   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004599-23-GB   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004599-23-ES   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004599-23-DE   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-004599-23-BE   Belgium;Canada;Germany;Greece;Israel;Italy;Spain;United Kingdom;United States
   Genkyotex Suisse SA
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-FR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Golexanolone
   Umecrine Cognition AB
      2023   Phase 1;Phase 2   EUCTR2022-000422-16-GR   Germany;Greece;Hungary;Italy;Serbia;Spain;Turkey;United Kingdom
      2023   Phase 1;Phase 2   EUCTR2022-000422-16-ES   Germany;Greece;Hungary;Italy;Serbia;Spain;Turkey;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2022-000422-16-HU   Germany;Greece;Hungary;Italy;Serbia;Spain;United Kingdom
GR3027
   Umecrine Cognition AB
      2023   Phase 1;Phase 2   EUCTR2022-000422-16-GR   Germany;Greece;Hungary;Italy;Serbia;Spain;Turkey;United Kingdom
      2023   Phase 1;Phase 2   EUCTR2022-000422-16-ES   Germany;Greece;Hungary;Italy;Serbia;Spain;Turkey;United Kingdom
      2022   Phase 1;Phase 2   EUCTR2022-000422-16-HU   Germany;Greece;Hungary;Italy;Serbia;Spain;United Kingdom
GS-9674
   Gilead Sciences, Inc.
      2017   Phase 2   EUCTR2016-002443-42-GB   Austria;Canada;United Kingdom;United States
GS-9674 100 MG
   Gilead Sciences, Inc.
      2017   Phase 2   EUCTR2016-002443-42-AT   Austria;Canada;United Kingdom;United States
GS-9674 30 MG
   Gilead Sciences, Inc.
      2017   Phase 2   EUCTR2016-002443-42-AT   Austria;Canada;United Kingdom;United States
GSK2330672
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2021   Phase 3   EUCTR2021-000007-21-IT   Argentina;Belgium;Canada;China;Czech Republic;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002416-41-IT   Australia;Canada;France;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   GlaxoSmithKline
      2017   Phase 2   NCT02966834   Australia;Canada;France;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States
      2014   Phase 2   NCT01899703   United Kingdom
   GlaxoSmithKline Research & Development Ltd
      2017   Phase 2   EUCTR2016-002416-41-PL   Australia;Canada;France;Japan;Netherlands;Poland;Spain;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002416-41-GB   Australia;Canada;France;Japan;Netherlands;Poland;Spain;United Kingdom;United States
   GlaxoSmithKline, S.A.
      2017   Phase 2   EUCTR2016-002416-41-ES   Australia;Canada;France;Italy;Japan;Netherlands;Poland;Spain;United Kingdom;United States
GSK2330672/linerixibat 40 MG
   GlaxoSmithKline Research & Development Limited
      2023   Phase 3   EUCTR2021-000007-21-ES   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000007-21-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2021-000007-21-CZ   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000007-21-FR   Argentina;Belgium;Brazil;Canada;China;Czech Republic;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2021-000007-21-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czech Republic;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
GYPP-06 (GKT137831 free base), C10071301-D
   Calliditas Therapeutics Suisse SA
      2022   Phase 2   EUCTR2021-001810-13-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-PL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-GR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Genkyotex Suisse SA
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-ES   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-HU   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Hesperidin
   Fujinaga Yukihisa
      2022   Phase 2   JPRN-jRCTs051210210   -
High protein high fiber diet
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2011   -   NCT01603199   Mexico
ICG
   University of Aarhus
      2013   Phase 1   NCT01879735   Denmark
INT-747
   AMC
      2017   Phase 2   EUCTR2016-002965-67-NL   Netherlands
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Intercept Pharmaceuticals
      2009   -   EUCTR2007-001425-10-NL   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-AT   Austria;France;Germany;Spain;United Kingdom
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-FR   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001425-10-ES   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-FR   Austria;France;Germany;Spain;United Kingdom
      2008   Phase 2   EUCTR2007-001424-12-ES   Austria;France;Germany;Spain;United Kingdom
      2007   Phase 2   NCT00570765   Austria;Canada;France;Germany;Spain;United Kingdom;United States
      2007   Phase 2   NCT00550862   Austria;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
   Intercept Pharmaceuticals, Inc.
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-NL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
INT-747, OCA
   INTERCEPT PHARMACEUTICALS INC.
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
IPN60190
   IPSEN Pharma SAS
      2021   Phase 3   EUCTR2019-004941-34-DE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Türkiye;United Kingdom;United States
      2020   Phase 3   EUCTR2019-004941-34-BE   Argentina;Belgium;Brazil;Canada;Chile;France;Germany;Italy;South Africa;Spain;Türkiye;United Kingdom;United States
   Ipsen Bioscience Inc
      2022   Phase 1   EUCTR2022-001883-91-FR   France
K-808
   Kowa Research Institute, Inc.
      2024   Phase 1   NCT06525311   Japan;United States
      2024   Phase 2   NCT06247735   Canada;Japan;United States
Linerixibat
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2021   Phase 3   EUCTR2021-000007-21-IT   Argentina;Belgium;Canada;China;Czech Republic;France;Germany;Greece;Italy;Japan;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States
   GlaxoSmithKline
      2022   -   NCT05448170   -
      2021   Phase 3   NCT04950127   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
      2020   Phase 3   NCT04167358   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Germany;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Switzerland;United Kingdom;United States
   GlaxoSmithKline K.K.
      2020   Phase 3   JPRN-jRCT2080225120   Argentina;Brazil;Canada;China;France;Germany;Italy;Mexico;Poland;Russian Federation;Spain;United Kingdom;United States
   Okawa Yasutoshi
      2021   Phase 3   JPRN-jRCT2071210048   Argentina;Belgium;Brazil;Bulgaria;Canada;China;France;Germany;Italy;Japan;Mexico;Poland;Russian Federation;United Kingdom;United States
Linerixibat (GSK2330672) 40 MG
   GlaxoSmithKline Research & Development Ltd
      2023   Phase 3   EUCTR2019-003158-10-BG   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003158-10-GR   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Switzerland;United Kingdom;United States
      2022   Phase 3   EUCTR2019-003158-10-BE   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003158-10-PL   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Switzerland;United Kingdom;United States
Linerixibat (GSK2330672) 45 MG
   GlaxoSmithKline Research & Development Ltd
      2020   Phase 3   EUCTR2019-003158-10-PL   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Switzerland;United Kingdom;United States
Linerixibat (GSK2330672) 45MG
   GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
      2020   Phase 3   EUCTR2019-003158-10-IT   Belgium;Bulgaria;Canada;France;Greece;Italy;Japan;Poland;United Kingdom;United States
   GlaxoSmithKline Research & Development Ltd
      2021   Phase 3   EUCTR2019-003158-10-FR   Belgium;Bulgaria;Canada;France;Greece;Italy;Japan;Poland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003158-10-PL   Argentina;Belgium;Brazil;Bulgaria;Canada;China;Czechia;France;Greece;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Switzerland;United Kingdom;United States
      2020   Phase 3   EUCTR2019-003158-10-GB   Canada;Japan;Poland;United Kingdom;United States
LJN452
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-001590-41-PL   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States
LJN452, 0,01 MG
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2015-001590-41-DE   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States
LJN452, 0,03 MG
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2015-001590-41-DE   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States
LJN452, 0,1 MG
   Novartis Pharma Services AG
      2016   Phase 2   EUCTR2015-001590-41-DE   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States
LUM001
   Lumena Pharmaceuticals, Inc.
      2013   -   EUCTR2013-000482-36-GB   United Kingdom;United States
   Mirum Pharmaceuticals, Inc.
      2015   Phase 2   NCT02321306   United Kingdom;United States
      2013   Phase 2   NCT01904058   Canada;United Kingdom;United States
LY3009104
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 2   EUCTR2018-003365-34-IT   Italy;United Kingdom;United States
   Eli Lilly and Company
      2019   Phase 2   EUCTR2018-003365-34-GB   Italy;United Kingdom;United States
MBX 8025
   CymaBay Therapeutics Inc.
      2016   Phase 2   EUCTR2015-002698-39-PL   Canada;Germany;Poland;United Kingdom;United States
      2015   Phase 2   EUCTR2015-002698-39-GB   Canada;Germany;Poland;United Kingdom;United States
      2015   Phase 2   EUCTR2015-002698-39-DE   Canada;Germany;Poland;United Kingdom;United States
MBX-8025
   CymaBay Therapeutics Inc.
      2016   Phase 2   EUCTR2015-002698-39-PL   Canada;Germany;Poland;United Kingdom;United States
      2015   Phase 2   EUCTR2015-002698-39-GB   Canada;Germany;Poland;United Kingdom;United States
      2015   Phase 2   EUCTR2015-002698-39-DE   Canada;Germany;Poland;United Kingdom;United States
   CymaBay Therapeutics, Inc.
      2022   Phase 3;Phase 4   EUCTR2020-005198-29-RO   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004348-27-DK   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005198-29-PL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-NL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-IT   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-HU   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-GR   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-FR   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005198-29-DE   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-BE   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-RO   Argentina;Australia;Belgium;Canada;Chile;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-PL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-NL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-IT   Argentina;Australia;Austria;Belgium;Canada;Chile;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-HU   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-DE   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-HU   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-GR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-003910-16-DE   Canada;Germany;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002996-91-GB   Canada;Germany;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002996-91-DE   Canada;Germany;United Kingdom;United States
      -   Phase 3   EUCTR2020-005198-29-CZ   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
MBX-8025, dsic
   CymaBay Therapeutics, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-003910-16-GB   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
MBX-8025, formulation 2
   CymaBay Therapeutics, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-003910-16-GB   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
Methotrexate
   National Center for Research Resources (NCRR)
      1994   Phase 3   NCT00004784   -
      1989   Phase 3   NCT00004748   -
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1994   Phase 3   NCT00006168   United States
Methylprednisolone
   West China Hospital
      2020   Phase 4   NCT04617561   China
Methylprednisolone and azathioprine
   Xiaoli Fan
      2021   Phase 4   NCT04933292   China
Methylprednisolone and mycophenolate mofetil
   Xiaoli Fan
      2021   Phase 4   NCT04933292   China
Minodronic acid
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012193   Japan
Modafinil
   Mayo Clinic
      2009   Phase 1   NCT00943176   United States
Moexipril
   Mayo Clinic
      2003   Phase 2   NCT00588302   United States
Mycophenolate mofetil
   West China Hospital
      2021   Phase 4   NCT04376528   China
Nalmefene
   Tharimmune Inc
      2025   Phase 2   NCT06733519   -
NCA 500MG
   Dr. Falk Pharma GmbH
      2022   Phase 2   EUCTR2021-001431-56-NO   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-NL   Austria;Belgium;Denmark;Finland;France;Germany;Lithuania;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-FR   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-FI   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-DK   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-DE   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-BE   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-AT   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
NGM282
   NGM Biopharmaceuticals, Inc
      2014   Phase 2   NCT02135536   Australia;New Zealand;United States
      2014   Phase 2   NCT02026401   Australia;United States
NI-0801
   NOVIMMUNE BV
      2011   -   EUCTR2011-001326-26-IT   Italy
   NovImmune S.A.
      2011   -   EUCTR2011-001326-26-GB   Italy;United Kingdom
   NovImmune SA
      2011   Phase 2   NCT01430429   Italy;United Kingdom
Norucholic acid (NCA) 500 MG
   Dr. Falk Pharma GmbH
      2022   Phase 2   EUCTR2021-001431-56-NO   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-NL   Austria;Belgium;Denmark;Finland;France;Germany;Lithuania;Netherlands;Norway;Poland;Spain;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-FR   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-FI   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-DK   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-DE   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-BE   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
      2022   Phase 2   EUCTR2021-001431-56-AT   Austria;Belgium;Denmark;Finland;France;Germany;Netherlands;Norway;Poland;Switzerland;United Kingdom
Obeticholic acid
   INTERCEPT PHARMACEUTICALS INC.
      2022   Phase 2   EUCTR2022-001241-20-IT   Argentina;Canada;Italy;Turkey;United States
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Intercept Pharmaceuticals
      2019   Phase 2   NCT04594694   Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
      2018   Phase 4   NCT03633227   Argentina;Australia;Belgium;Brazil;Canada;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United States
      2014   Phase 4   NCT02308111   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 2   NCT01865812   United States
      2012   Phase 3   NCT01473524   Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2009   -   EUCTR2007-001425-10-DE   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   -   EUCTR2007-001425-10-AT   Austria;France;Germany;Netherlands;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom
      2009   Phase 2   EUCTR2007-001424-12-DE   Austria;France;Germany;Spain;United Kingdom
      2008   -   EUCTR2007-001425-10-GB   Austria;France;Germany;Netherlands;Spain;United Kingdom
   Intercept Pharmaceuticals Inc.
      2018   Phase 4   EUCTR2014-005012-42-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 4   EUCTR2014-005012-42-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005012-42-FR   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2014-005012-42-ES   Argentina;Australia;Austria;Belgium;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-NL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   University of Aarhus
      2016   Early Phase 1   NCT03253276   Denmark
Obeticholic acid 10 MG
   Intercept Pharmaceuticals
      2022   -   NCT05293938   United States
Obeticholic acid 5 MG
   Intercept Pharmaceuticals
      2022   -   NCT05293938   United States
      2022   Phase 2   NCT05239468   United States
Obeticholic acid tablets
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2021   Phase 3   NCT04956328   China
   Nanjing Chia-tai Tianqing Pharmaceutical
      2021   Phase 3   NCT05450887   China
OCA
   AMC
      2017   Phase 2   EUCTR2016-002965-67-NL   Netherlands
   INTERCEPT PHARMACEUTICALS, INC.
      2012   Phase 3   EUCTR2011-004728-36-IT   Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Intercept Pharmaceuticals
      2024   Phase 3   NCT06488911   Argentina;Australia;Belgium;Canada;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Netherlands;Norway;Spain;Turkey;United Kingdom;United States
      2019   Phase 2   NCT04594694   Australia;Austria;Belgium;Croatia;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Spain;Sweden;United Kingdom
      2018   Phase 4   NCT03633227   Argentina;Australia;Belgium;Brazil;Canada;Estonia;Germany;Hungary;Italy;Lithuania;Spain;United States
      2014   Phase 4   NCT02308111   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;Former Serbia and Montenegro;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2013   Phase 2   NCT01865812   United States
      2012   Phase 3   NCT01473524   Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2009   Phase 2   EUCTR2007-001424-12-GB   Austria;France;Germany;Spain;United Kingdom
   Intercept Pharmaceuticals, Inc.
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-NL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-ES   Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   Nanjing Chia-tai Tianqing Pharmaceutical
      2021   Phase 3   NCT05450887   China
   Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
      2021   Phase 3   NCT06715319   China
Ocaliva
   INTERCEPT PHARMACEUTICALS INC.
      2018   Phase 4   EUCTR2017-001762-13-IT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
   Intercept Pharmaceuticals Inc.
      2018   Phase 4   EUCTR2014-005012-42-PT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2017   Phase 4   EUCTR2014-005012-42-NL   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-HU   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-DE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2016   Phase 4   EUCTR2014-005012-42-BG   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-LT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-GB   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-FI   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-EE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-DK   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-BE   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
      2015   Phase 4   EUCTR2014-005012-42-AT   Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Denmark;Estonia;Finland;France;Germany;Hong Kong;Hungary;Israel;Italy;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Serbia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States
   Intercept Pharmaceuticals, Inc.
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-LT   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-HU   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 4   EUCTR2017-001762-13-ES   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-EE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-DE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-001762-13-BE   Argentina;Australia;Belgium;Brazil;Estonia;Germany;Hungary;Italy;Lithuania;Spain;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-SE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-PL   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-GB   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-DE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-BE   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
      2012   Phase 3   EUCTR2011-004728-36-AT   Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Poland;Spain;Sweden;United Kingdom;United States
   University of Leipzig
      2019   -   NCT04076527   Germany
Ocaliva 10MG
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
Ocaliva 5MG
   INTERCEPT PHARMACEUTICALS INC.
      2022   Phase 2   EUCTR2022-001241-20-IT   Argentina;Canada;Italy;Turkey;United States
   Intercept Pharmaceuticals, Inc.
      2020   Phase 2   EUCTR2018-002575-17-PL   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-LT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-HR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GR   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-GB   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-DE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-CZ   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2020   Phase 2   EUCTR2018-002575-17-AT   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-SK   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States
      2019   Phase 2   EUCTR2018-002575-17-HU   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-FR   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-ES   Australia;Austria;Belgium;Croatia;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Lithuania;Netherlands;Norway;Poland;Slovakia;Slovenia;Spain;Sweden;United Kingdom
      2019   Phase 2   EUCTR2018-002575-17-BE   Australia;Austria;Belgium;Croatia;Czech Republic;Czechia;Estonia;France;Germany;Greece;Hungary;Ireland;Israel;Korea, Republic of;Lithuania;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom
Olumiant
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 2   EUCTR2018-003365-34-IT   Italy;United Kingdom;United States
   Eli Lilly and Company
      2019   Phase 2   EUCTR2018-003365-34-GB   Italy;United Kingdom;United States
Part 1: LJN452
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02516605   Canada;Germany;Poland;Russian Federation;United Kingdom;United States
Part 2: LJN452 dose level 1
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02516605   Canada;Germany;Poland;Russian Federation;United Kingdom;United States
Part 2: LJN452 dose level 2
   Novartis Pharmaceuticals
      2015   Phase 2   NCT02516605   Canada;Germany;Poland;Russian Federation;United Kingdom;United States
Pemafibrate
   Kowa Co., Ltd.
      2017   Phase 1   JPRN-jRCT2080223672   Japan
   Shinshu University Faculty of Medicine, Department of Gastroenterology
      2020   -   JPRN-UMIN000039350   Japan
Pentoxifylline
   The Cleveland Clinic
      2010   Phase 2   NCT01249092   United States
Phenylbutyrate
   Juntendo University
      2014   -   JPRN-UMIN000012782   Japan
   Saiseikai Yokohama City Tobu Hospital
      2010   -   JPRN-UMIN000003802   Japan
Prednisone
   Han Ying
      2024   Phase 2/Phase 3   NCT06591468   China
Probiotic
   Sun Yat-sen University
      2020   Phase 2   NCT03521297   China
PVT201
   Parvus Therapeutics, Inc.
      2024   Phase 1   NCT06798454   Australia
Pyridoxine 10MG BP
   Barts and The London NHS Trust
      2007   Phase 4   EUCTR2006-006742-34-GB   United Kingdom
Questran
   Albireo
      2013   Phase 1   NCT02963077   -
Raltegravir
   University of Alberta
      2021   Phase 2   NCT03954327   Canada
Rhudex 100 MG (127 MG rhudex choline salt) granules
   DR. FALK PHARMA GMBH
      2021   Phase 2   EUCTR2020-001961-34-IT   Belgium;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom
   Dr. Falk Pharma GmbH
      2021   Phase 2   EUCTR2020-001961-34-SK   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom
      2021   Phase 2   EUCTR2020-001961-34-PL   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom
      2021   Phase 2   EUCTR2020-001961-34-DE   Belgium;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;United Kingdom
      2020   Phase 2   EUCTR2020-001961-34-NL   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom
      2020   Phase 2   EUCTR2020-001961-34-HU   Hungary
      2020   Phase 2   EUCTR2020-001961-34-BE   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom
Rhudex 25 MG (31.75 MG rhudex choline salt) granules
   DR. FALK PHARMA GMBH
      2021   Phase 2   EUCTR2020-001961-34-IT   Belgium;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom
   Dr. Falk Pharma GmbH
      2021   Phase 2   EUCTR2020-001961-34-SK   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom
      2021   Phase 2   EUCTR2020-001961-34-PL   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom
      2021   Phase 2   EUCTR2020-001961-34-DE   Belgium;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;United Kingdom
      2020   Phase 2   EUCTR2020-001961-34-NL   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom
      2020   Phase 2   EUCTR2020-001961-34-HU   Hungary
      2020   Phase 2   EUCTR2020-001961-34-BE   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom
Rhudex 50 MG (63.5 MG rhudex choline salt) granules
   DR. FALK PHARMA GMBH
      2021   Phase 2   EUCTR2020-001961-34-IT   Belgium;Czechia;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;Spain;United Kingdom
   Dr. Falk Pharma GmbH
      2021   Phase 2   EUCTR2020-001961-34-SK   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom
      2021   Phase 2   EUCTR2020-001961-34-PL   Belgium;Germany;Hungary;Netherlands;Poland;Slovakia;United Kingdom
      2021   Phase 2   EUCTR2020-001961-34-DE   Belgium;Germany;Hungary;Italy;Netherlands;Poland;Slovakia;United Kingdom
      2020   Phase 2   EUCTR2020-001961-34-NL   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom
      2020   Phase 2   EUCTR2020-001961-34-HU   Hungary
      2020   Phase 2   EUCTR2020-001961-34-BE   Belgium;Germany;Hungary;Netherlands;Slovakia;United Kingdom
Rifampicin
   The University Of Adelaide
      2020   Phase 3   EUCTR2018-004011-44-GB   Australia;Finland;Netherlands;Sweden;United Kingdom
   The University of Adelaide
      2020   Phase 4   EUCTR2018-004011-44-SE   Australia;Finland;Netherlands;Sweden;United Kingdom
      2020   Phase 4   EUCTR2018-004011-44-FI   Australia;Finland;Netherlands;Sweden;United Kingdom
Rifaximin
   Xiangya Hospital of Central South University
      2021   -   ChiCTR2100046346   China
Risedronic acid
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012193   Japan
Rituximab
   Newcastle-upon-Tyne Hospitals NHS Trust
      2012   Phase 2   NCT02376335   United Kingdom
   The Newcastle upon Tyne Hospitals NHS Foundation Trust
      2012   Phase 2   EUCTR2012-000145-12-GB   United Kingdom
   University of California, Davis
      2007   Phase 1/Phase 2   NCT00364819   United States
S-adenosyl-L-methionine
   Pomeranian Medical University Szczecin
      2015   Phase 4   NCT02557360   Poland
S-adenosyl-methionine (same) capsules
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   Phase 2   NCT00125281   United States
Saroglitazar magnesium 1 MG
   Zydus Therapeutics Inc.
      2024   Phase 3   NCT06427395   Argentina;Turkey;United States
      2023   Phase 2;Phase 3   EUCTR2022-001634-10-ES   Argentina;Colombia;Iceland;Italy;Spain;Turkey;United Kingdom;United States
      2022   Phase 2/Phase 3   NCT05133336   Argentina;Iceland;Turkey;United States
      2022   Phase 2;Phase 3   EUCTR2022-001634-10-IS   Iceland;Italy;Spain;United States
Saroglitazar magnesium 2 MG
   Zydus Therapeutics Inc.
      2023   Phase 2;Phase 3   EUCTR2022-001634-10-ES   Argentina;Colombia;Iceland;Italy;Spain;Turkey;United Kingdom;United States
      2022   Phase 2/Phase 3   NCT05133336   Argentina;Iceland;Turkey;United States
      2022   Phase 2;Phase 3   EUCTR2022-001634-10-IS   Iceland;Italy;Spain;United States
      2017   Phase 2   NCT03112681   United States
Saroglitazar magnesium 4 MG
   Zydus Therapeutics Inc.
      2017   Phase 2   NCT03112681   United States
Seladelpar
   CymaBay Therapeutics, Inc.
      2022   Phase 3;Phase 4   EUCTR2020-005198-29-RO   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2022   Phase 3   EUCTR2020-004348-27-DK   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005198-29-PL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-NL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-IT   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-HU   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-GR   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-FR   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-005198-29-DE   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3;Phase 4   EUCTR2020-005198-29-BE   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-RO   Argentina;Australia;Belgium;Canada;Chile;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-PL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-NL   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-IT   Argentina;Australia;Austria;Belgium;Canada;Chile;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-HU   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;United Kingdom;United States
      2021   Phase 3   EUCTR2020-004348-27-DE   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Turkey;Ukraine;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-NL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-FR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-BE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2019   Phase 3   EUCTR2018-001171-20-AT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-PL   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-IT   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-HU   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-GR   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3   EUCTR2018-001171-20-DE   Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 3;Phase 4   EUCTR2017-003910-16-GB   Argentina;Australia;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
      2018   Phase 2;Phase 3   EUCTR2017-003910-16-DE   Canada;Germany;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002996-91-GB   Canada;Germany;United Kingdom;United States
      2017   Phase 2   EUCTR2016-002996-91-DE   Canada;Germany;United Kingdom;United States
      -   Phase 3   EUCTR2020-005198-29-CZ   Argentina;Australia;Austria;Belgium;Canada;Chile;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
   Gilead Sciences
      2023   Phase 3   NCT06051617   Argentina;Australia;Canada;Chile;Korea, Republic of;Turkey;United States
Seladelpar / MBX-8025 200 MG
   CymaBay Therapeutics, Inc.
      2015   Phase 2   NCT02609048   Canada;Germany;Poland;United Kingdom;United States
Seladelpar / MBX-8025 50 MG
   CymaBay Therapeutics, Inc.
      2015   Phase 2   NCT02609048   Canada;Germany;Poland;United Kingdom;United States
Seladelpar 10 MG
   CymaBay Therapeutics, Inc.
      2021   Phase 3   NCT04620733   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
      2018   Phase 3   NCT03602560   Argentina;Australia;Austria;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
   Gilead Sciences
      2023   Phase 3   NCT06060665   Canada;United States
Seladelpar 10 MG capsule
   Gilead Sciences
      2017   Phase 3   NCT03301506   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
Seladelpar 10 MG or less
   Gilead Sciences
      2021   Phase 1   NCT04950764   Korea, Republic of;Spain;United Kingdom;United States
Seladelpar 5 MG
   CymaBay Therapeutics, Inc.
      2021   Phase 3   NCT04620733   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States
Seladelpar 5 MG capsule
   Gilead Sciences
      2017   Phase 3   NCT03301506   Argentina;Australia;Austria;Belgium;Canada;Chile;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Spain;Switzerland;Turkey;United Kingdom;United States
Seladelpar 5-10 MG
   CymaBay Therapeutics, Inc.
      2018   Phase 3   NCT03602560   Argentina;Australia;Austria;Belgium;Canada;Chile;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States
Setanaxib
   Calliditas Therapeutics Suisse SA
      2022   Phase 2   NCT05014672   Australia;Austria;Belgium;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-SE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-PL   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-DE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-CZ   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-BE   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2   EUCTR2021-001810-13-AT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-GR   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Israel;Italy;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
   Genkyotex Suisse SA
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-IT   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2022   Phase 2;Phase 3   EUCTR2021-001810-13-ES   Australia;Austria;Belgium;Canada;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
      2021   Phase 2;Phase 3   EUCTR2021-001810-13-HU   Australia;Austria;Belgium;Canada;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;New Zealand;Poland;Spain;Sweden;Switzerland;United Kingdom;United States
Sortis 10 MG
   Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology
      2005   -   EUCTR2005-002160-28-AT   Austria
Standard OF care: udca
   Intercept Pharmaceuticals
      2022   -   NCT05293938   United States
Sublimated mare milk
   National Scientific Medical Center, Kazakhstan
      2018   -   NCT03665519   Kazakhstan
T cell injection targeting CD19 chimeric antigen receptor
   PersonGen BioTherapeutics (Suzhou) Co., Ltd.
      2024   Early Phase 1   NCT06417398   -
Tauroursodeoxycholic acid capsules
   Beijing Friendship Hospital
      2009   Phase 3   NCT01857284   China
TDF/FTC/LPV/R
   University of Alberta
      2012   -   NCT01614405   Canada
Tenofovir disoproxil
   University of Alberta
      2021   Phase 2   NCT03954327   Canada
Tetrathiomolybdate
   George Brewer
      2006   Phase 3   NCT00805805   United States
Thiamine
   Aarhus University Hospital
      2021   Phase 2   EUCTR2020-004935-26-DK   Denmark
   Henning Grønbæk
      2021   Phase 4   NCT04893993   Denmark
Tiamin DAK
   Aarhus University Hospital
      2021   Phase 2   EUCTR2020-004935-26-DK   Denmark
Tiamin SAD
   Aarhus University Hospital
      2021   Phase 2   EUCTR2020-004935-26-DK   Denmark
Tigecycline
   Wyeth is now a wholly owned subsidiary of Pfizer
      2006   Phase 1   NCT00406237   Puerto Rico;United States
TQA3526
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2020   Phase 2   NCT04278820   China
Tropifexor
   Novartis Pharma Services AG
      2017   Phase 2   EUCTR2015-001590-41-PL   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States
      2016   Phase 2   EUCTR2015-001590-41-DE   Canada;China;Germany;Poland;Russian Federation;United Kingdom;United States
Udca
   Beijing 302 Hospital
      2016   Phase 1/Phase 2   NCT02965911   China
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2021   Phase 3   NCT04956328   China
   Dr. Falk Pharma GmbH
      2008   Phase 4   NCT01510860   Germany
   Gunma Liver Study Group
      2003   -   JPRN-C000000225   Japan
   Han Ying
      2024   Phase 2/Phase 3   NCT06591468   China
      2024   Early Phase 1   NCT06591455   China
      2023   Phase 2/Phase 3   NCT06174402   China
   Longhua Hospital ShangHai University of Traditional Chinese Medicine
      2020   Phase 0   ChiCTR2000037244   China
   Longhua Hospital Shanghai University of Traditional Chinese Medicine
      2022   Phase 0   ChiCTR2200063119   China
   Longhua Hospital, Shanghai University of Traditional Chinese Medicine
      2019   Phase 0   ChiCTR1900027043   China
   Longhua Hospital, Shanghai University of traditional Chinese Medicine
      2019   Phase 0   ChiCTR1900026813   China
   Nanjing Chia-tai Tianqing Pharmaceutical
      2021   Phase 3   NCT05450887   China
   Peking Union Medical College Hosipital
      2018   -   ChiCTR1800020160   China
   Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
      2021   Phase 3   NCT06715319   China
   University of Leipzig
      2019   -   NCT04076527   Germany
   Xiangya Hospital of Central South University
      2021   -   ChiCTR2100046346   China
   Xijing Hospital of Digestive Diseases
      2023   Phase 2/Phase 3   NCT05749822   China
      2017   Phase 2/Phase 3   NCT06365424   China
      2016   Phase 3   NCT02916641   China
      2016   Phase 3   NCT02916290   China
      2016   Phase 3   NCT02823366   China
      2016   Phase 3   NCT02823353   China
Umbilical cord derived mesenchymal stem cell (UC -MSC) transplantation
   Vinmec Research Institute of Stem Cell and Gene Technology
      2019   Phase 1/Phase 2   NCT04522869   Vietnam
Ursodeoxycholic acid
   DR. FALK PHARMA GMBH
      2009   Phase 3   EUCTR2007-004040-70-IT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
   Dr. Falk Pharma GmbH
      2013   -   EUCTR2007-004040-70-PL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-004040-70-GB   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004040-70-DK   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004040-70-AT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   Phase 4   NCT01510860   Germany
      2008   Phase 4   EUCTR2008-001524-31-NL   Germany;Netherlands
      2008   -   EUCTR2008-001524-31-DE   Germany;Netherlands
      2008   Phase 3   EUCTR2007-004040-70-SE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-NL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-LT   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-HU   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-FR   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-FI   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004040-70-ES   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-DE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2006   -   EUCTR2006-003712-22-DE   Germany
   GlaxoSmithKline
      2014   Phase 2   NCT01899703   United Kingdom
   Gongli Hospital of Shanghai Pudong New Area
      2023   Phase 0   ChiCTR2300068755   China
   Han Ying
      2024   Phase 2/Phase 3   NCT06591468   China
      2024   Early Phase 1   NCT06591455   China
   Humanity and Health Research Centre
      2017   -   NCT03188146   China
   Instituto Mexicano del Seguro Social
      2020   Phase 3   NCT04751188   Mexico
   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
      2016   Phase 3   NCT02937012   Mexico
   Intercept Pharmaceuticals
      2007   Phase 2   NCT00550862   Austria;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria
   Mirum Pharmaceuticals, Inc.
      2013   Phase 2   NCT01904058   Canada;United Kingdom;United States
   National Scientific Medical Center, Kazakhstan
      2018   -   NCT03665519   Kazakhstan
   Peking Union Medical College Hospital
      2020   Phase 4   NCT04650243   China
   Robert Chunhua Zhao, MD, PhD
      2011   Phase 1   NCT01440309   China
   The University Of Adelaide
      2020   Phase 3   EUCTR2018-004011-44-GB   Australia;Finland;Netherlands;Sweden;United Kingdom
   The University of Adelaide
      2020   Phase 4   EUCTR2018-004011-44-SE   Australia;Finland;Netherlands;Sweden;United Kingdom
      2020   Phase 4   EUCTR2018-004011-44-FI   Australia;Finland;Netherlands;Sweden;United Kingdom
   West China Hospital
      2020   Phase 4   NCT04617561   China
   Xiangya Hospital of Central South University
      2021   -   ChiCTR2100046346   China
Ursodeoxycholic acid 300MG capsule
   University of Sao Paulo General Hospital
      2016   -   NCT03489889   Brazil
Ursodeoxycholic acid 300MG tablet
   University of Sao Paulo General Hospital
      2016   -   NCT03489889   Brazil
Ursodeoxycholic acid capsules
   Beijing Friendship Hospital
      2009   Phase 3   NCT01857284   China
   Shanghai Municipal Hospital of Traditional Chinese Medicine
      2021   Phase 0   ChiCTR2000037243   China
Ursodeoxycholic acid combination OF immunosuppressive agents
   Xiaoli Fan
      2016   -   NCT02936596   China
Ursodeoxycholic acid combined with total glucosides OF paeony
   West China Hospital
      2021   Phase 4   NCT04618575   China
Ursodeoxycholic acid only
   West China Hospital
      2021   Phase 4   NCT04618575   China
UrsodeoxycholsäURE
   Medizinische Universität Graz
      2011   -   EUCTR2011-004681-15-AT   Austria
Ursodiol
   National Center for Research Resources (NCRR)
      1994   Phase 3   NCT00004784   -
      1989   Phase 3   NCT00004748   -
Ursofalk
   Dr. Falk Pharma GmbH
      2013   -   EUCTR2007-004040-70-PL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   Phase 3   EUCTR2007-004040-70-GB   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004040-70-DK   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2009   -   EUCTR2007-004040-70-AT   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004040-70-SE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-NL   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-LT   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-HU   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-FR   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-FI   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   Phase 3   EUCTR2007-004040-70-ES   Austria;Denmark;Finland;France;Germany;Hungary;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
      2008   -   EUCTR2007-004040-70-DE   Austria;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Spain;Sweden;United Kingdom
Ursofalk® 500 MG FILM-coated tablets
   Dr. Falk Pharma GmbH
      2008   Phase 4   EUCTR2008-001524-31-NL   Germany;Netherlands
      2008   -   EUCTR2008-001524-31-DE   Germany;Netherlands
Ursofalk® 500 MG filmtabletten
   Dr. Falk Pharma GmbH
      2006   -   EUCTR2006-003712-22-DE   Germany
Ursofalk® capsules
   Dr. Falk Pharma GmbH
      2008   Phase 4   EUCTR2008-001524-31-NL   Germany;Netherlands
      2008   -   EUCTR2008-001524-31-DE   Germany;Netherlands
Ustekinumab
   Janssen-Cilag International N.V.
      2011   -   EUCTR2011-000554-31-SE   Canada;France;Germany;Italy;Sweden;United Kingdom;United States
      2011   Phase 2   EUCTR2011-000554-31-GB   Canada;France;Germany;Italy;Sweden;United Kingdom;United States
Ustekinumab 180 MG
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01389973   Canada;United States
Ustekinumab 45 MG
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01389973   Canada;United States
Ustekinumab 90 MG
   Janssen Research & Development, LLC
      2011   Phase 2   NCT01389973   Canada;United States
Vitamin D
   Juntendo University School of Medicine
      2013   -   JPRN-UMIN000012489   Japan
      2013   -   JPRN-UMIN000012193   Japan
   Yilihamu·Abilitifu
      2021   -   NCT06309589   China
Volixibat
   Mirum Pharmaceuticals Inc.
      2022   Phase 2   EUCTR2021-001389-39-IT   Canada;France;Germany;Israel;Italy;United Kingdom;United States
   Mirum Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-001389-39-FR   Canada;France;Germany;Israel;Italy;United Kingdom;United States
      2021   Phase 2   NCT05050136   Argentina;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Netherlands;Spain;United Kingdom;United States
Volixibat potassium
   Mirum Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-001389-39-DE   Canada;France;Germany;Israel;Italy;United Kingdom;United States
Zoledronic acid
   Tokai University School of Medicine
      2018   -   JPRN-UMIN000031384   Japan